Increasing molecular diversity is creating a need for the reinvention of process development and control strategies.

Process Development and Control for New Modalities

Learning from early market failures, the biopharma industry has worked to improve the fate of antibody drug conjugates.

Improving the Fate of ADCs

There are many benefits of employing a reformulation strategy, but companies must also overcome a variety of challenges too.

Reformulating Success

Topic

Feliza Mirasol is the science editor for 

Articles

Deeper biological understanding and technology innovations have improved the fate of ADC development.

ADCs Reap the Benefits of Continual Research and Process Improvements

Kenji Tabata, PhD, is senior vice-president, head of Discovery Intelligence, Applied Research & Operations, at Japan-based pharmaceutical company Astellas.

Through the integration of human expertise, artificial intelligence, and automation robotics, bio/pharma companies can more efficiently target drug discovery efforts with bigger payoff.

Leveraging Artificial Intelligence and Human Know-How to Accelerate Drug Discovery

Generate Biomedicines published a preprint describing technology that can generate novel proteins towards desired functional or other properties.

Generate Biomedicines Uses AI to Create Proteins That Have Never Existed

The guidance discusses statistical approaches for BE comparisons and focuses on how to use these approaches both generally and in specific situations. 

FDA Publishes Draft Guidance on Statistical Approaches to Establishing Bioequivalence

Results from Eisai and Biogen’s Alzheimer's treatment, lecanemab, indicated significantly slowed cognitive decline in patients relative to placebo.

Eisai and BioGen Alzheimer’s Drug Shows Promising Results in Phase III Study

Mike Hennessy Jr. is the President and CEO of 

Science news can be just so weird, or weirdly useful, that everything else recedes as we ponder whether it is true and what consequences it might bring.

Of Mice and Men and Armadillos

Biotech startup, Cradle, has raised $5.4 million in seed funding with an AI-enabled design platform that allows for the synthetic building of cell factories to produce proteins.

Biotech Startup Raises $5.4M to Develop AI-Designed Protein Machines and Cell Factories

Rozaleen Dash is a post-doctoral fellow in the Department of Chemical Engineering at the Indian Institute of Technology (Delhi). 

 was a research associate at the DBT Centre of Excellence for Biopharmaceutical Technology at the Indian Institute of Technology under the guidance of Professor Anurag S. Rathore, Department of Chemical Engineering, Indian Institute of Technology, Delhi, India.

Anurag S. Rathore is a professor in the Department of Chemical Engineering at the Indian Institute of Technology Delhi and a member of 

l's Editorial Advisory Board, Tel. +91.9650770650, asrathore@biotechcmz.com.

A novel mathematical approach for fitting concentration-response curves is proposed that offers a more accurate estimation of potency data.

Mathematical Modeling of Cell-based Potency Data for mAb Biotherapeutics

Editor of Pharmaceutical Technology Europe

Companies need to consider and address formulation challenges to employ a successful reformulation strategy.

Considerations for a Successful Reformulation Strategy

Marina Necdina is a business development manager, former pharma analyst, and research scientist.

New medications show exciting outcomes for weight loss.